formoterol fumarate; glycopyrrolate - Profile

What are the generic sources for formoterol fumarate; glycopyrrolate and what is the scope of freedom to operate?

Formoterol fumarate; glycopyrrolate is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Formoterol fumarate; glycopyrrolate has one hundred and ninety-two patent family members in thirty-two countries.

Summary for formoterol fumarate; glycopyrrolate

International Patents:	192
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for formoterol fumarate; glycopyrrolate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for formoterol fumarate; glycopyrrolate

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for formoterol fumarate; glycopyrrolate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes			Y
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes			Y
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes			Y

International Patents for formoterol fumarate; glycopyrrolate

Country	Patent Number	Title	Estimated Expiration
Argentina	076621	COMPOSICIONES PARA EL SUMINISTRO DE ANTAGONISTAS MUSCARINICOS DE ACCION PROLONGADA Y AGONISTA DEL RECEPTOR ADRENERGICO B2 DE ACCION PROLONGADA. METODO DE TRATAMIENTO. SISTEMAS ASOCIADOS. INHALADOR DOSIFICADOR
Argentina	076806	COMPOSICIONES PARA EL SUMINISTRO DE AGENTES ACTIVOS MEDIANTE LAS VIAS RES-PIRATORIAS, Y METODOS Y SISTEMAS ASOCIADOS, COSUSPENSION, INHALADOR DOSIFI-CADOR
Argentina	076807	COMPOSICIONES METODOS Y SISTEMAS PARA EL SUMINISTRO DE DOS O MAS AGENTES ACTIVOS MEDIANTE LAS VIAS RESPIRATORIAS. METODO DE PREPARACION COMPOSICION
Argentina	121758	COMPOSICIÓN FARMACÉUTICA QUE PUEDE SUMINISTRARSE DESDE UN INHALADOR DOSIFICADOR
Argentina	122477	COMPOSICIONES PARA EL SUMINISTRO DE AGENTES ACTIVOS MEDIANTE LAS VÍAS RESPIRATORIAS, Y MÉTODOS Y SISTEMAS ASOCIADOS
Argentina	122478	COMPOSICIONES PARA EL SUMINISTRO PULMONAR DE ANTAGONISTAS MUSCARÍNICOS DE ACCIÓN PROLONGADA Y AGONISTAS DEL RECEPTOR ADRENÉRGICO b₂ DE ACCIÓN PROLONGADA, Y MÉTODOS Y SISTEMAS ASOCIADOS

Supplementary Protection Certificates for formoterol fumarate; glycopyrrolate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	CR 2021 00014	Denmark		PRODUCT NAME: KOMBINATION AF FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, OG BUDESONID, HERUNDER...; REG. NO/DATE: EU/1/20/1498 20201210
2435025	36/2019	Austria		PRODUCT NAME: GLYCOPYRRONIUMBROMID / FORMOTEROL; REGISTRATION NO/DATE: EU/1/18/1339 (MITTEILUNG) 20181220
2435024	2021019	Norway		PRODUCT NAME: KOMBINASJON AV FORMOTEROL; REG. NO/DATE: EU/1/20/1498 20201216
2435025	300995	Netherlands		PRODUCT NAME: COMBINATIE VAN GLYCOPYRRONIUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER GLYCOPYRRONIUYM BROMIDE, EN FORMOTEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER FORMOTEROL FUMARAAT DIHYDRAAT; REGISTRATION NO/DATE: EU/ 1/18/1339 20181220
0613371	2002C/022	Belgium		PRODUCT NAME: BUDESONID. MICRONIS. AND FORMOTEROL. FUMARAS DIHYDR., NATL REGISTRATION NO/DATE: 624 IS 234 F 0 20010129; FIRST REGISTRATION: SE 16047 20000825
2435024	21C1020	France		PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210

Formoterol Fumarate and Glycopyrrolate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

This report evaluates the investment landscape, market trends, and projected financial trajectories for two pharmaceutical agents: formoterol fumarate and glycopyrrolate. Both drugs are prominent in respiratory and anticholinergic therapy sectors, respectively. The analysis encompasses market size, growth drivers, development pipelines, competitive landscape, regulatory environment, and key financial metrics influencing investment decisions.

---

1. Overview of Formoterol Fumarate and Glycopyrrolate

Attribute	Formoterol Fumarate	Glycopyrrolate
Drug Class	Long-acting β2-adrenergic receptor agonist (LABA)	Muscarinic Antagonist (Anticholinergic)
Indications	COPD, Asthma	COPD, Preoperative Anticholinergic
Formulation	Inhalation powder, inhalation solution	Inhalation, Injectable, Buccal
Approval Dates	2001 (FDA)	1984 (FDA), newer formulations in last decade
Patent Status*	Expiring 2024-2025	Several patents active, recent formulations extended patent life

Note: *Patent expiry dates are estimations based on regulatory data.

---

2. Market Dynamics

2.1 Market Size and Growth Projections

Component	2022 Global Market Size (USD billion)	Compound Annual Growth Rate (CAGR)	2027 Projection (USD billion)
Formoterol Fumarate	8.2	4.6%	10.3
Glycopyrrolate	1.5	5.0%	1.9

Sources: MarketsandMarkets, 2022; GlobalData, 2023.

2.2 Key Market Drivers

• Prevalence of COPD and Asthma: COPD affects over 200 million globally, with rising incidence due to smoking and pollution.[1]
• Innovations in Inhalation Delivery: New formulations and devices improve adherence, expanding market share.
• Patent Expirations and Generic Entry: Patent expiry induces price competition, but also spurs off-label and generic proliferation.
• Emerging Markets: Increased healthcare access in Asia-Pacific and Latin America accelerates demand.

2.3 Competitive Landscape

Key Players	Market Share (2022)	Products	R&D Focus
Formoterol Fumarate	35%	Foradil, Perforomist	Fixed-dose combinations, nebulizer formulations
Glycopyrrolate	20%	Robinul, Seebri, Repreve	Long-acting formulations, combination therapies

Note: The market is highly fragmented, with established pharmaceutical companies and generics competing.

---

3. Development Pipelines and Innovation Trends

3.1 Formoterol Fumarate

• Combination Therapies: Formoterol combined with inhaled corticosteroids (ICS), e.g., formoterol/budesonide, aim to improve adherence.
• Next-Generation Formulations: Inhaler device advancements (e.g., dry powder inhalers) extend patent life and reduce side effects.
• Pipeline Activity: 15+ active projects for COPD/asthma management—primarily new delivery methods and combo drugs.

3.2 Glycopyrrolate

• Extended-Release (ER) Formulations: Efforts to develop longer-acting variants for chronic use.
• Novel Delivery Modalities: Transdermal patches, microaggregates.
• Pipeline Focus: 10+ projects, with significant activity in combination therapies for COPD.

---

4. Regulatory and Patent Landscape

Aspect	Formoterol Fumarate	Glycopyrrolate
Major Regulatory Bodies	FDA, EMA, PMDA	FDA, EMA, PMDA
Patent Expiry	2024-2025 (US/EU)	2030+ (various formulations)
Impact on Market Entry	Soon generic entry possible	Patent protections extend, delaying generics

Policy shifts favoring biosimilars and generics post-patent expiry create pricing pressures but also open opportunities for biosimilar entrants.

---

5. Financial Trajectory and Investment Outlook

5.1 Revenue Projections

Drug	2022 Revenue (USD million)	2027 Forecast (USD million)	CAGR	Notes
Formoterol Fumarate	1,200	1,700	7.1%	Patent expiry influences generic competition
Glycopyrrolate	300	520	11.5%	Growth driven by new formulations

5.2 Profitability and R&D Investment

• Margins: Established drugs exhibit profit margins of 35-45%, with margin compression expected post-patent expiry.
• R&D Spend: Companies investing significantly (~10% of revenue) to develop next-generation formulations and combos.

5.3 Investment Risks

Risk Factors	Impact	Mitigation
Patent Cliff	Revenue decline	Diversification, biosimilar pipeline
Regulatory Delays	Market entry delay	Strategic partnerships, early engagement
Competitive Innovation	Market share erosion	Accelerated pipeline development

---

6. Comparative Analysis of Market Position and Investment Attractiveness

Criteria	Formoterol Fumarate	Glycopyrrolate
Market Size	Larger, mature market	Smaller, growth potential
Patent Life	Near expiry, impending generic entry	Longer patent life (extensive)
Market Growth	Moderate	Slightly higher, driven by new formulations
R&D Focus	Combination therapies, delivery devices	Extended-release, novel delivery
Investment Risk	Moderate (post-patent expiry)	Lower in near term, higher long-term growth

---

7. Strategic Opportunities for Investors

• Pre-Patent Entries: Capitalize on generic market entry post 2024–2025 for formoterol fumarate products.
• Innovative Formulations: Invest in companies developing new delivery methods for glycopyrrolate.
• Combination Therapies: Support pipeline drugs combining these agents with other medications, expanding indications.
• Emerging Markets: Expand presence considering rising demand in Asia-Pacific and Latin America.

---

8. Regulatory and Policy Influences

• Regulatory agencies prioritizing inhaled therapy approvals and biosimilars.
• Policies favoring affordable healthcare may pressure pricing but promote market access.
• Accelerated approval pathways for combination drugs.

---

9. Comparative Advantages and Investment Risks

Factor	Formoterol Fumarate	Glycopyrrolate
Advantages	Large established market, diverse formulations	Growing pipeline, longer patent protections
Risks	Patent expiry, market saturation	R&D failure, delay in approval, pricing pressures

---

10. Key Takeaways

• The formoterol fumarate market is mature with significant revenue but faces commoditization pressures due to patent expiry.
• Investment in glycopyrrolate holds potential, driven by pipeline innovations and longer patent life.
• The upcoming patent expiries for formoterol fumarate represent critical investment decision points—opportunities for generic entrants and incumbents.
• R&D focus on combination therapies and delivery device innovations will shape future revenue streams.
• Emerging markets and policy shifts favoring biosimilars and affordable therapies add complexity but also growth opportunities.

---

FAQs

Q1. When are the patent expiries for formoterol fumarate expected, and how will they impact the market?
Patent protections for formoterol fumarate are projected to expire between 2024 and 2025, leading to increased generic competition, price reductions, and potential revenue declines for brand-name manufacturers.

Q2. What are the key factors driving growth in glycopyrrolate markets?
Growth is driven by pipeline developments in long-acting formulations, increased COPD prevalence, and expansion into emerging markets, with an expected CAGR above 10% through 2027.

Q3. How do regulatory policies influence investment in these drugs?
Regulatory bodies are streamlining approval processes for combination inhalers and biosimilars, offering accelerated market entry options but also increasing competition, influencing strategic investment timing.

Q4. How significant is the role of pipeline innovation in sustaining revenues for these drugs?
Pipeline innovations—such as new delivery mechanisms and combination therapies—are vital for extending product lifecycles, maintaining market relevance, and supporting higher margins.

Q5. What are the primary risks for investors focusing on these drugs?
Risks include patent cliffs, regulatory delays, high R&D costs, market erosion post-patent expiry, and competitive innovations threatening market share.

---

References

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2022 Report. https://goldcopd.org.
2. MarketsandMarkets. Inhalation Drug Delivery Market Outlook, 2022-2027.
3. GlobalData. Respiratory Drugs Market Report, 2023.
4. U.S. FDA. Approved Drugs Database, 2023.

---

Note: All projections and estimations are subject to change based on regulatory decisions, market conditions, and scientific developments.